Magnetic Resonance Imaging in the Clinical Care for Uveal Melanoma Patients-A Systematic Review from an Ophthalmic Perspective.
Myriam G Jaarsma-CoesLisa KlaassenMarina MarinkovicGregorius P M LuytenT H Khanh VuTeresa A FerreiraJan-Willem M BeenakkerPublished in: Cancers (2023)
Conversely to most tumour types, magnetic resonance imaging (MRI) was rarely used for eye tumours. As recent technical advances have increased ocular MRI's diagnostic value, various clinical applications have been proposed. This systematic review provides an overview of the current status of MRI in the clinical care of uveal melanoma (UM) patients, the most common eye tumour in adults. In total, 158 articles were included. Two- and three-dimensional anatomical scans and functional scans, which assess the tumour micro-biology, can be obtained in routine clinical setting. The radiological characteristics of the most common intra-ocular masses have been described extensively, enabling MRI to contribute to diagnoses. Additionally, MRI's ability to non-invasively probe the tissue's biological properties enables early detection of therapy response and potentially differentiates between high- and low-risk UM. MRI-based tumour dimensions are generally in agreement with conventional ultrasound (median absolute difference 0.5 mm), but MRI is considered more accurate in a subgroup of anteriorly located tumours. Although multiple studies propose that MRI's 3D tumour visualisation can improve therapy planning, an evaluation of its clinical benefit is lacking. In conclusion, MRI is a complementary imaging modality for UM of which the clinical benefit has been shown by multiple studies.
Keyphrases
- contrast enhanced
- magnetic resonance imaging
- diffusion weighted imaging
- computed tomography
- end stage renal disease
- magnetic resonance
- healthcare
- ejection fraction
- palliative care
- chronic kidney disease
- high resolution
- randomized controlled trial
- pain management
- mass spectrometry
- prognostic factors
- patient reported outcomes
- clinical trial
- clinical practice
- multidrug resistant
- stem cells